Enovis Crescita futura

Future criteri di controllo 0/6

Enovis prevede che gli utili e i ricavi cresceranno rispettivamente di 88.6% e 7.4% all'anno. Si prevede che l'EPS crescerà di 101.7% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 6.8% in 3 anni.

Informazioni chiave

88.6%

Tasso di crescita degli utili

101.7%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili	17.1%
Tasso di crescita dei ricavi	7.4%
Rendimento futuro del capitale proprio	6.8%
Copertura analitica	Good
Ultimo aggiornamento	07 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Previsioni di crescita degli utili e dei ricavi

NYSE:ENOV - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	2,391	6	274	544	10
12/31/2025	2,228	-31	218	488	11
12/31/2024	2,101	-115	-41	252	11
9/27/2024	2,002	-121	-62	94	N/A
6/28/2024	1,914	-107	-60	71	N/A
3/29/2024	1,817	-103	-37	91	N/A
12/31/2023	1,707	-54	13	135	N/A
9/29/2023	1,661	-112	-100	31	N/A
6/30/2023	1,627	-159	-106	19	N/A
3/31/2023	1,594	-23	-146	-34	N/A
12/31/2022	1,563	-39	-161	-56	N/A
9/30/2022	1,553	1	-23	76	N/A
7/1/2022	1,530	54	47	154	N/A
4/1/2022	1,491	-109	154	257	N/A
12/31/2021	1,426	-103	252	356	N/A
10/1/2021	1,855	-48	282	389	N/A
7/2/2021	2,301	-18	262	371	N/A
4/2/2021	2,565	21	222	330	N/A
12/31/2020	1,121	-75	187	302	N/A
10/2/2020	3,131	53	132	238	N/A
7/3/2020	3,172	39	102	214	N/A
4/3/2020	3,460	42	127	259	N/A
12/31/2019	3,327	8	6	131	N/A
9/27/2019	3,014	10	62	191	N/A
6/28/2019	2,692	21	94	203	N/A
3/29/2019	2,344	66	74	157	N/A
12/31/2018	2,193	108	157	226	N/A
9/28/2018	2,492	-115	133	205	N/A
6/29/2018	2,813	-84	N/A	154	N/A
3/30/2018	3,100	-92	N/A	176	N/A
12/31/2017	1,937	28	N/A	219	N/A
9/29/2017	3,239	154	N/A	260	N/A
6/30/2017	3,161	147	N/A	289	N/A
3/31/2017	3,043	151	N/A	272	N/A
12/31/2016	3,186	138	N/A	247	N/A
9/30/2016	3,435	144	N/A	254	N/A
7/1/2016	3,637	126	N/A	293	N/A
4/1/2016	3,933	138	N/A	321	N/A
12/31/2015	3,434	158	N/A	304	N/A
9/25/2015	4,112	204	N/A	336	N/A
6/26/2015	4,307	259	N/A	416	N/A
3/27/2015	4,481	397	N/A	451	N/A
12/31/2014	4,624	370	N/A	386	N/A
9/26/2014	4,589	322	N/A	377	N/A
6/27/2014	4,440	299	N/A	314	N/A
3/28/2014	4,314	160	N/A	309	N/A
12/31/2013	4,207	154	N/A	362	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che ENOV rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che ENOV rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che ENOV rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di ENOV ( 7.4% all'anno) crescerà più lentamente rispetto al mercato US ( 8.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di ENOV ( 7.4% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di ENOV sarà basso tra 3 anni ( 6.8 %).

Enovis Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates fall by 13%

Enovis Corporation Narrows Earnings Guidance for the Year 2024

Price target decreased by 7.1% to US$67.00

Consensus EPS estimates fall by 20%

Enovis Corporation Narrows Revenue Guidance for the Year 2024

Enovis Corporation Updates Earnings Guidance for the Year 2024

Recent updates

Consensus EPS estimates fall by 13%

Third quarter 2024 earnings: EPS misses analyst expectations

Enovis Corporation Narrows Earnings Guidance for the Year 2024

Enovis Corporation to Report Q3, 2024 Results on Nov 06, 2024

Price target decreased by 7.1% to US$67.00

Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt

Enovis Corp Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

Enovis Continues to Redefine Revision Knee Surgery with the Addition of Emowr Revision Knee

It's A Story Of Risk Vs Reward With Enovis Corporation (NYSE:ENOV)

Enovis Corporation Introduces Star Ankle, Now with E+ Polyethylene for Unmatched Durability

Consensus EPS estimates fall by 20%

Second quarter 2024 earnings: EPS misses analyst expectations

Enovis Corporation Narrows Revenue Guidance for the Year 2024

Enovis Corporation to Report Q2, 2024 Results on Aug 07, 2024

Enovis Languishing Despite Respectable Performance

Enovis Releases AltiVate Reverse Glenoid System, Widening Range of Patients Who May Be Treated with AltiVate Reverse

Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt

Enovis: Solid Growth, But Unstable Financial Footing

Enovis Corporation Updates Earnings Guidance for the Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Enovis Corporation (NYSE:ENOV) Might Not Be As Mispriced As It Looks

Enovis Corporation to Report Q1, 2024 Results on May 02, 2024

Enovis Corporation, Annual General Meeting, May 20, 2024

Price target increased by 8.6% to US$75.20

Full year 2023 earnings: EPS exceeds analyst expectations

Enovis Corporation Provides Earnings Guidance for the Year 2024

Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)

Enovis Corporation to Report Q4, 2023 Results on Feb 22, 2024

Enovis Introduces the DonJoy ROAM™ OA Knee Brace

Is Enovis (NYSE:ENOV) Using Too Much Debt?

Investors Holding Back On Enovis Corporation (NYSE:ENOV)

Enovis Corporation Announces Leadership Transition Plan

Consensus EPS estimates fall by 87%

No longer forecast to breakeven

Calculating The Fair Value Of Enovis Corporation (NYSE:ENOV)

Enovis Corporation to Report Q3, 2023 Results on Nov 07, 2023

Enovis Making Good Choices, But Not Seeing The Rewards

Enovis Corporation signed an agreement to acquire Limacorporate S.p.A. from MIR Capital S.C.A., SICAR, EQT VII, EQT Partners AB and EQT VII for €800 million.

Enovis Corporation signed an agreement to acquire Limacorporate S.p.A. from MIR Capital S.C.A., SICAR, EQT VII, EQT Partners AB and EQT VII for €800 million.

Is Enovis (NYSE:ENOV) A Risky Investment?

New major risk - Revenue and earnings growth

Enovis Corporation Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)

Enovis Corporation: Things Are Looking Good As Guidance Is Raised

Enovis Corporation to Report Q2, 2023 Results on Aug 03, 2023

Price target increased by 8.0% to US$68.17

Enovis Corporation (NYSE:ENOV) acquired Novastep Inc. from Amplitude Surgical SA (ENXTPA:AMPLI).

Forecast breakeven date pushed back to 2024

We Think Enovis (NYSE:ENOV) Has A Fair Chunk Of Debt

Independent Director notifies of intention to sell stock

Enovis Corporation Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: EPS misses analyst expectations

Enovis Corporation Q4 2022 Earnings Preview

Is Enovis (NYSE:ENOV) A Risky Investment?

Enovis Corporation to Report Q4, 2022 Results on Feb 23, 2023

Is Enovis Corporation (NYSE:ENOV) Worth US$60.5 Based On Its Intrinsic Value?

Enovis Corporation Announces the Launch of the Dynaclip Delta and Dynaclip Quattro Bone Staples

Enovis Receives FDA Approval of Patient Specific Instrumentation for STAR Ankle

Enovis Corporation Announces Introduction of DynaNail Helix

High number of new directors

Third quarter 2022 earnings: EPS misses analyst expectations

Enovis Corporation Provides Earnings Guidance for the Year 2022

Enovis Corporation reports Q3 earnings beat; updates FY22 guidance

Is Enovis (NYSE:ENOV) A Risky Investment?

Now 21% undervalued after recent price drop

Enovis Corporation to Report Q3, 2022 Results on Nov 02, 2022

Is Enovis Corporation (NYSE:ENOV) Trading At A 27% Discount?